Novo Nordisk Plunges as Morgan Stanley Warns Semaglutide Patent Cliff Is Worse Than Markets Think

The Quick Take

• Morgan Stanley cut Novo Nordisk to Underweight, arguing that semaglutide patent cliff risks are more severe than the market has priced into NVO's current valuation
• The downgrade sent NVO shares plunging as Morgan Stanley's analysis warns that loss of exclusivity on the blockbuster GLP-1 drug Ozempic/Wegovy could materially compress Novo Nordisk's revenue outlook beyond consensus estimates
• The call intensifies scrutiny of the GLP-1 drug class competitive dynamics, with Eli Lilly's tirzepatide positioned to gain market share and Indian generic manufacturers watching the patent timeline closely

Morgan Stanley downgraded Novo Nordisk to Underweight — its most negative rating — citing concerns that the semaglutide patent cliff represents a more serious and earlier-than-priced threat to the Danish pharmaceutical giant's revenue trajectory. The downgrade triggered a sharp sell-off in NVO shares as institutional investors reassessed the valuation assumptions that had supported Novo Nordisk's emergence as one of Europe's most valuable companies on the strength of semaglutide's blockbuster success as Ozempic (for type-2 diabetes) and Wegovy (for obesity). Morgan Stanley's Underweight call implies conviction that the risks extend beyond ordinary patent expiry concerns: the analyst team argues that the combination of compounded semaglutide competition, pending biosimilar development programs, and potential IP challenges creates a confluence of patent cliff risks that the current valuation does not adequately discount.

The investment implications of Morgan Stanley's call ripple across the pharmaceutical sector in both directions. For Novo Nordisk itself, an Underweight designation from a bulge-bracket bank with one of the most influential pharmaceutical research teams in institutional markets carries significant weight, particularly on a company where the bull case depends heavily on semaglutide maintaining protected pricing through the 2020s. For Eli Lilly, which competes in the GLP-1 market with tirzepatide (Mounjaro for diabetes, Zepbound for obesity), NVO's patent cliff risk creates a relative advantage: if semaglutide pricing erodes earlier than expected, Lilly's next-generation GLP-1 could capture a larger share of the premium-priced market. The competitive dynamics between NVO and LLY in the GLP-1 category have been the dominant theme in large-cap pharmaceutical equity since 2024.

For investors tracking the patent cliff thesis, the most critical variable is the legal landscape around compounded semaglutide — injectable formulations produced by compounding pharmacies that the FDA had permitted as a temporary measure during the Ozempic shortage. If the FDA moves to restrict compounded semaglutide access, the near-term patent protection window for NVO widens; if compounding restrictions are loosened, the de facto patent cliff begins earlier. Morgan Stanley's call appears to reflect the risk that regulatory and legal proceedings around compounded GLP-1s will resolve in a way that is unfavorable to Novo Nordisk's exclusive market position, though the full analytical rationale behind the Underweight rating and any associated price target requires direct access to the Morgan Stanley research note.

Synthesized from 1 source.